



Demographics and socioeconomic

Total Population (in 1000) (2020)	11,673.03
Population <1 year of age (in 1000) (2020)	236.87
Population 1 year of age (in 1000) (2020)	237.13
Population <5 years of age (in 1000) (2020)	1,185.50
Women of childbearing age (in 1000) (2020)	9,579.26
Infant Mortality Rate (per 1000 live births) (2011-16)*	24.0
Gross national income (US\$ per capita) current value (2020)	3,200.0
National Health Expenditure Public (2018)	4.5
National Health Expenditure Private (2018)	1.7

* study

Immunization system highlights

- There is a comprehensive multi-year plan for immunization covering 2016-2020.
- A standing national technical advisory group on immunization (NITAG) with formal written terms of reference exists. The group met 15 times in 2020.
- 92% of spending on routine immunization is financed using government funds.
- 100% of spending on vaccine purchases is financed using government funds.
- A national nominal electronic immunization registry is in place.


Vaccine Introduction

	Year
Bacterial Meningitis	
<i>Haemophilus influenzae</i> type b	2000
Hepatitis B	2000
HPV	2017
Influenza	2010
MMR1	2000
MMR2	2018
Pentavalent	2000
Pneumococcal Conjugate	2014
Rotavirus	2008
Tdap	
Tetavalent DPT-Hib or DPT-HepB	
Yellow Fever	2003

Immunization Schedule

BOL	Doses					
	1	2	3	4	5	6
BCG	B					
HepB pediatric						
DTP-Hib						
DTP-Hib-HepB	M2	M4	M6	M18-M23	Y4	
DTP-Hib-IPV						
DTP-Hib-HepB-IPV						
DTP						
Influenza pediatric	M6-M11	M12-M23				
IPV	M2					
OPV		M4	M6	M18-M23	Y4	
MMR	M12	M18-M23				
Pneumoco conjugate	M2	M4	M6			
Rotavirus	M2	M4				
Td	1st contact					
Tdap						
HPV						

Vaccination Coverage




Surveillance indicators

Acute flaccid paralysis (AFP)	2020
Number of AFP suspected cases	16
AFP rate per 100,000 population <15 years old	0.45
% of cases with 1 adequate samples	75
% of cases investigated within <48 hours	100
% sites reporting	0


Measles-rubella (MR)	2020
Number of MR suspected cases	137
% of cases with adequate investigation	94
% of cases with adequate blood samples	94
% of samples received in laboratory <=5 days	82
% of laboratory samples results <=4 days	90




Polio3 coverage and AFP rate per 100,000 children <15 years of age




DTP3 coverage and number of reported diphtheria and pertussis cases




Number of tetanus (no neonatal) and neonatal tetanus cases



Proportion of municipalities by coverage range with DTP3 in children <1 years of age



DTP1-DTP3 and DTP1-MMR1 Dropout Rate



Vaccine Stockout

BOL	2013	2014	2015	2016	2017	2018	2019	2020
AD syringes	●	●	●		●	●	●	●
BCG	●	●	●	●	●	●	●	●
Disposable syringes		●	●	●	●			
DTP	●	●	●	●	●	●	●	●
HepB	●		●		●	●	●	●
Hib			●		●			●
Influenza	●	●	●	●	●	●	●	●
IPV				●	●	●	●	●
Measles	●	●	●	●	●	●	●	●
Pneumo. conjugate	●	●	●	●	●	●	●	●
Polio	●	●	●	●	●	●	●	●
Reconst. syringes	●	●	●	●	●	●	●	●
Rotavirus	●	●	●	●	●	●	●	●
Safety boxes	●	●	●	●	●	●	●	●
Tdap			●		●			
TT	●	●	●	●	●	●	●	●
Yellow fever	●	●	●	●	●	●	●	●

Legend

- NB/nb-newborn
- M/m -month
- Y/y-year
- WCBA-women of childbearing age
- with stockout
- no stockout
- no data available